查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1813355

IVF遺傳風險評分市場預測（至2032年）：按測試類型、技術、應用、最終用戶和地區進行的全球分析

IVF Genetic Risk Scoring Market Forecasts to 2032 - Global Analysis By Test Type (Single-Gene Risk Scoring, Polygenic Risk Scoring, Carrier Screening Panels and Whole Genome Sequencing), Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球 IVF 遺傳風險評分市場預計在 2025 年達到 3.632 億美元，到 2032 年將達到 8.813 億美元，預測期內的複合年成長率為 13.5%。

體外受精（IVF）遺傳風險評分（GRS）是一項尖端生殖技術，用於評估體外受精（IVF）胚胎的遺傳健康狀況。透過分析特定的遺傳標記、單核苷酸多態性（SNP）和多基因風險因素，GRS可以預測胚胎未來患有特定遺傳疾病或病症的可能性。此評分系統使臨床醫生和準父母能夠做出明智的胚胎選擇決策，從而提高健康懷孕的幾率並降低遺傳疾病的風險。 IVF GRS整合了先進的基因組學、生物資訊學和生殖醫學技術，以更高的精準度和預測性提供個人化的不孕症治療。

生殖技術的進步

基因組學、生物資訊學和胚胎篩檢領域的快速創新推動了IVF遺傳風險評分（GRS）的普及。多基因風險因子和單核苷酸多態性（SNP）檢測技術的提升，使臨床醫生能夠更有信心地進行個人化胚胎選擇。人工智慧主導的分析技術與新一代定序（NGS）平台的整合進一步提高了預測準確性，使GRS成為現代不孕症治療的基石。這些進步透過改善臨床療效和降低遺傳性疾病的發病率，推動了市場擴張。

高成本且可近性有限

高成本和有限的可及性嚴重阻礙了IVF基因風險評分市場的成長。這些障礙將大量人群排除在早期基因組篩檢之外，並阻礙了公平的醫療創新。新興地區缺乏保險覆蓋和基礎設施，進一步加劇了差距，抑制了需求，並減緩了臨床整合。因此，市場擴張仍受到限制，其變革潛力在服務不足的地區仍未充分發揮。

遺傳性疾病發生率不斷上升

囊腫纖維化、泰-薩克斯病和BRCA相關癌症等遺傳性疾病的發生率不斷上升，加劇了對預測性胚胎篩檢的需求。 IVF遺傳風險評分提供了一個主動的解決方案，能夠及早識別遺傳易感性，從而改善生殖決策。隨著臨床醫生和準父母意識的不斷增強，GRS有望成為生育治療通訊協定的標準組成部分。這種日益成長的臨床需求代表著巨大的成長機遇，尤其是在遺傳疾病高發生率地區。

胚胎受損的風險

基因檢測過程中胚胎損傷的風險嚴重削弱了人們對體外受精（IVF）遺傳風險評分的信心，阻礙了臨床醫生和準父母的採用。對侵入性切片檢查技術及其對可存活胚胎的潛在危害的擔憂引發了倫理和安全方面的擔憂，阻礙了監管部門的核准和投資者的興趣。這種不確定性阻礙了市場成長，限制了臨床整合，並加劇了公眾的懷疑，尤其是在生育政策保守、基因組學素養較低的地區。

COVID-19的影響

新冠疫情擾亂了體外受精（IVF）基因風險評分市場，擾亂了生育治療，推遲了胚胎移植，並增加了患者的心理壓力。診所在關閉期間暫停營運，導致周期延遲和需求減少。然而，這場危機加速了人們對數位化諮商和基因組篩檢的認知，刺激了長期成長。隨著服務恢復，人們對個人化胚胎選擇和基因分析的興趣日益濃厚，推動了市場復甦和創新。

預測期內，性狀篩檢部分預計將成為最大的部分

預測期內，性狀篩檢細分市場預計將佔據最大市場佔有率，這得益於其在評估多基因風險和遺傳疾病方面廣泛的臨床效用。透過分析特定基因標記，可以早期發現與慢性疾病、認知障礙和身體異常相關的性狀。它是一種非侵入性技術，適用於現有的體外受精 (IVF) 工作流程，因此具有高度的擴充性。隨著個人化醫療的興起，性狀篩檢正成為胚胎選擇的重要組成部分，並推動其佔據主導的市場佔有率。

預計在預測期內，不孕症治療診所部門的複合年成長率最高。

由於對綜合生殖健康服務的需求不斷成長，預計生育診所細分市場將在預測期內呈現最高成長率。這些診所提供端到端的IVF解決方案，包括遺傳諮詢、胚胎篩檢和個人化治療方案。採用先進的GRS平台將改善患者預後並提高臨床效率。隨著人們對遺傳風險評分的認知不斷提高，生育診所正逐漸成為一個重要的銷售管道，尤其是在患者數量眾多且實驗室設備先進的都市區。

比最大的地區

在預測期內，由於生育治療基礎設施的不斷擴大、人們對遺傳疾病的認知不斷提高以及政府的支持政策，預計亞太地區將佔據最大的市場佔有率。由於人口結構的變化和中階經濟實力的不斷增強，中國、印度和日本等國家正在擴大採用體外受精 (IVF)。區域性對基因組學和數位健康的投資正在進一步加速IVF GRS的整合。領先的生育診所和研究機構的存在使亞太地區成為全球IVF GRS領域的主導力量。

複合年成長率最高的地區：

預計北美將在預測期內呈現最高的複合年成長率。這得益於其強大的醫療基礎設施、較高的患者認知度以及對基因檢測強力的監管支持。該地區率先採用精準醫療和先進的體外受精 (IVF)通訊協定，為 GRS 的擴張提供了肥沃的土壤。生物技術公司與生育中心之間的策略聯盟正在推動創新和可及性。優惠的報銷政策和對個人化生殖醫學日益成長的需求預計將使北美在市場成長方面保持領先地位。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5.全球IVF 遺傳風險評分市場（依測試類型）

  • 單基因風險評分
  • 多基因風險評分
  • 承運人篩檢小組
  • 全基因組序列分析

6.全球IVF 遺傳風險評分市場（依技術）

  • NGS（次世代定序）
  • 微陣列
  • 基於PCR的方法
  • 人工智慧和機器學習演算法

7.全球IVF 遺傳風險評分市場（按應用）

  • 胚胎選擇
  • 疾病風險預測
  • 房產篩檢
  • 個人化試管嬰兒通訊協定
  • 其他用途

8.全球IVF 遺傳風險評分市場（依最終用戶）

  • 不孕不育診所
  • 體外受精中心
  • 遺傳諮詢公司
  • 研究機構

9.全球IVF 遺傳風險評分市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Natera, Inc.
  • CooperSurgical, Inc.
  • Thermo Fisher Scientific, Inc.
  • Vitrolife AB
  • Igenomix
  • Genea Limited
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Invicta Genetics
  • Juno Genetics, US Inc.
  • Bioarray SL
  • Reproductive Health Science Ltd.
  • Genesis Genetics Ltd.
Product Code: SMRC30802

According to Stratistics MRC, the Global IVF Genetic Risk Scoring Market is accounted for $363.2 million in 2025 and is expected to reach $881.3 million by 2032 growing at a CAGR of 13.5% during the forecast period. IVF Genetic Risk Scoring (GRS) is a cutting-edge reproductive technology that evaluates the genetic health of embryos created through in vitro fertilization (IVF). By analyzing specific genetic markers, single-nucleotide polymorphisms (SNPs), and polygenic risk factors, GRS predicts the likelihood of an embryo developing certain inherited diseases or conditions later in life. This scoring system enables clinicians and prospective parents to make informed decisions about embryo selection, aiming to improve the chances of a healthy pregnancy and reduce the risk of genetic disorders. IVF GRS integrates advanced genomics, bioinformatics, and reproductive medicine to personalize fertility care with greater precision and foresight.

Market Dynamics:

Driver:

Advancements in Reproductive Technologies

Rapid innovations in genomics, bioinformatics, and embryo screening are propelling the adoption of IVF Genetic Risk Scoring (GRS). Enhanced precision in detecting polygenic risk factors and single-nucleotide polymorphisms (SNPs) enables clinicians to personalize embryo selection with greater confidence. Integration of AI-driven analytics and next-generation sequencing (NGS) platforms is further improving predictive accuracy, making GRS a cornerstone of modern fertility care. These advancements are driving market expansion by elevating clinical outcomes and reducing the incidence of inherited disorders.

Restraint:

High Cost and Limited Accessibility

High cost and limited accessibility significantly hinder the growth of the IVF genetic risk scoring market by restricting adoption to affluent urban centers. These barriers exclude vast populations from early-stage genomic screening, stalling equitable healthcare innovation. The lack of insurance coverage and infrastructure in emerging regions further exacerbates disparities, curbing demand and slowing clinical integration. As a result, market expansion remains constrained, with transformative potential unrealized across underserved geographies.

Opportunity:

Rising Incidence of Genetic Disorders

The increasing prevalence of hereditary conditions such as cystic fibrosis, Tay-Sachs, and BRCA-related cancers is intensifying demand for predictive embryo screening. IVF Genetic Risk Scoring offers a proactive solution by enabling early identification of genetic predispositions, thereby improving reproductive decision-making. As awareness grows among clinicians and prospective parents, GRS is poised to become a standard component of fertility protocols. This rising clinical need presents a significant growth opportunity, especially in regions with high rates of inherited diseases.

Threat:

Risk of Embryo Damage

The risk of embryo damage during genetic testing significantly undermines confidence in IVF genetic risk scoring, deterring adoption among clinicians and prospective parents. Concerns over invasive biopsy techniques and potential harm to viable embryos raise ethical and safety alarms, stalling regulatory approvals and investor interest. This uncertainty hampers market growth, limits clinical integration, and fuels public skepticism, especially in regions with conservative reproductive policies and limited genomic literacy.

Covid-19 Impact

The COVID-19 pandemic disrupted the IVF Genetic Risk Scoring market by halting fertility treatments, delaying embryo transfers, and increasing emotional stress for patients. Clinics paused operations during lockdowns, leading to postponed cycles and reduced demand. However, the crisis accelerated digital consultations and genomic screening awareness, fostering long-term growth. As services resumed, heightened interest in personalized embryo selection and genetic profiling positioned the market for resilient recovery and innovation.

The trait screening segment is expected to be the largest during the forecast period

The trait screening segment is expected to account for the largest market share during the forecast period, due to its broad clinical utility in assessing polygenic risks and inherited conditions. By analyzing specific genetic markers, this segment enables early detection of traits linked to chronic diseases, cognitive disorders, and physical anomalies. Its non-invasive nature and compatibility with existing IVF workflows make it highly scalable. As personalized medicine gains traction, trait screening is becoming integral to embryo selection, driving its leadership in market share.

The fertility clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the fertility clinics segment is predicted to witness the highest growth rate, due to rising demand for integrated reproductive services. These clinics offer end-to-end IVF solutions, including genetic counseling, embryo screening, and personalized treatment plans. Their adoption of advanced GRS platforms enhances patient outcomes and boosts clinical efficiency. As awareness of genetic risk scoring grows, fertility clinics are emerging as key distribution channels, particularly in urban centers with high patient volumes and advanced lab capabilities.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its expanding fertility infrastructure, rising awareness of genetic disorders, and supportive government initiatives. Countries like China, India, and Japan are witnessing increased IVF adoption, driven by demographic shifts and growing middle-class affordability. Regional investments in genomics and digital health are further accelerating GRS integration. The presence of leading fertility clinics and research institutions positions Asia Pacific as a dominant force in the global IVF GRS landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust healthcare infrastructure, high patient awareness, and strong regulatory support for genetic testing. The region's early adoption of precision medicine and advanced IVF protocols makes it fertile ground for GRS expansion. Strategic collaborations between biotech firms and fertility centers are enhancing innovation and accessibility. Favorable reimbursement policies and growing demand for personalized reproductive care are expected to sustain North America's leadership in market growth.

Key players in the market

Some of the key players profiled in the IVF Genetic Risk Scoring Market include Illumina, Inc., Agilent Technologies, Inc., Natera, Inc., CooperSurgical, Inc., Thermo Fisher Scientific, Inc., Vitrolife AB, Igenomix, Genea Limited, PerkinElmer, Inc., Quest Diagnostics Incorporated, Invicta Genetics, Juno Genetics, US Inc., Bioarray S.L., Reproductive Health Science Ltd. and Genesis Genetics Ltd.

Key Developments:

In July 2025, Thermo Fisher Scientific has agreed to acquire Sanofi's sterile manufacturing site in Ridgefield, New Jersey. This expansion aims to bolster U.S. drug product manufacturing capabilities, enhancing capacity to meet the increasing demand from pharmaceutical and biotech customers.

In July 2020, PerkinElmer partnered with Sonora Quest Laboratories to expand COVID-19 testing in Arizona. This collaboration aimed to increase testing capacity in response to rising case numbers, supported by funding from the state of Arizona.

Test Types Covered:

  • Single-Gene Risk Scoring
  • Polygenic Risk Scoring
  • Carrier Screening Panels
  • Whole Genome Sequencing

Technologies Covered:

  • NGS (Next-Generation Sequencing)
  • Microarray
  • PCR-Based Methods
  • AI & Machine Learning Algorithms

Applications Covered:

  • Embryo Selection
  • Disease Risk Prediction
  • Trait Screening
  • Personalized IVF Protocols
  • Other Applications

End Users Covered:

  • Fertility Clinics
  • IVF Centers
  • Genetic Counseling Firms
  • Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global IVF Genetic Risk Scoring Market, By Test Type

  • 5.1 Introduction
  • 5.2 Single-Gene Risk Scoring
  • 5.3 Polygenic Risk Scoring
  • 5.4 Carrier Screening Panels
  • 5.5 Whole Genome Sequencing

6 Global IVF Genetic Risk Scoring Market, By Technology

  • 6.1 Introduction
  • 6.2 NGS (Next-Generation Sequencing)
  • 6.3 Microarray
  • 6.4 PCR-Based Methods
  • 6.5 AI & Machine Learning Algorithms

7 Global IVF Genetic Risk Scoring Market, By Application

  • 7.1 Introduction
  • 7.2 Embryo Selection
  • 7.3 Disease Risk Prediction
  • 7.4 Trait Screening
  • 7.5 Personalized IVF Protocols
  • 7.6 Other Applications

8 Global IVF Genetic Risk Scoring Market, By End User

  • 8.1 Introduction
  • 8.2 Fertility Clinics
  • 8.3 IVF Centers
  • 8.4 Genetic Counseling Firms
  • 8.5 Research Institutes

9 Global IVF Genetic Risk Scoring Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Illumina, Inc.
  • 11.2 Agilent Technologies, Inc.
  • 11.3 Natera, Inc.
  • 11.4 CooperSurgical, Inc.
  • 11.5 Thermo Fisher Scientific, Inc.
  • 11.6 Vitrolife AB
  • 11.7 Igenomix
  • 11.8 Genea Limited
  • 11.9 PerkinElmer, Inc.
  • 11.10 Quest Diagnostics Incorporated
  • 11.11 Invicta Genetics
  • 11.12 Juno Genetics, US Inc.
  • 11.13 Bioarray S.L.
  • 11.14 Reproductive Health Science Ltd.
  • 11.15 Genesis Genetics Ltd.

List of Tables

  • Table 1 Global IVF Genetic Risk Scoring Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 3 Global IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 4 Global IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 5 Global IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 6 Global IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 7 Global IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 8 Global IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 9 Global IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 10 Global IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 11 Global IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 12 Global IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 13 Global IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 14 Global IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 15 Global IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 16 Global IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 17 Global IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 18 Global IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 19 Global IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 20 Global IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 21 Global IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 22 Global IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 23 North America IVF Genetic Risk Scoring Market Outlook, By Country (2024-2032) ($MN)
  • Table 24 North America IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 25 North America IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 26 North America IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 27 North America IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 28 North America IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 29 North America IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 30 North America IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 31 North America IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 32 North America IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 33 North America IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 34 North America IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 35 North America IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 36 North America IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 37 North America IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 38 North America IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 39 North America IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 40 North America IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 41 North America IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 42 North America IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 43 North America IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 44 North America IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 45 Europe IVF Genetic Risk Scoring Market Outlook, By Country (2024-2032) ($MN)
  • Table 46 Europe IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 47 Europe IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 48 Europe IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 49 Europe IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 50 Europe IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 51 Europe IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 52 Europe IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 53 Europe IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 54 Europe IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 55 Europe IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 56 Europe IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 57 Europe IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 58 Europe IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 59 Europe IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 60 Europe IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 61 Europe IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 62 Europe IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 63 Europe IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 64 Europe IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 65 Europe IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 66 Europe IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 67 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Country (2024-2032) ($MN)
  • Table 68 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 69 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 70 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 71 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 72 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 73 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 74 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 75 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 76 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 77 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 78 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 79 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 80 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 81 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 82 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 83 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 84 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 85 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 86 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 87 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 88 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 89 South America IVF Genetic Risk Scoring Market Outlook, By Country (2024-2032) ($MN)
  • Table 90 South America IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 91 South America IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 92 South America IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 93 South America IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 94 South America IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 95 South America IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 96 South America IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 97 South America IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 98 South America IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 99 South America IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 100 South America IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 101 South America IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 102 South America IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 103 South America IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 104 South America IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 105 South America IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 106 South America IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 107 South America IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 108 South America IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 109 South America IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 110 South America IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 111 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Country (2024-2032) ($MN)
  • Table 112 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 113 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 114 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 115 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 116 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 117 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 118 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 119 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 120 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 121 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 122 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 123 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 124 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 125 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 126 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 127 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 128 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 129 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 130 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 131 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 132 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)